NASDAQ:CLLS - Cellectis Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.67
  • Forecasted Upside: 119.41 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$15.80
▲ +0.62 (4.08%)
1 month | 3 months | 12 months
Get New Cellectis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CLLS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CLLS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$34.67
▲ +119.41% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cellectis in the last 3 months. The average price target is $34.67, with a high forecast of $39.00 and a low forecast of $32.00. The average price target represents a 119.41% upside from the last price of $15.80.

Buy

The current consensus among 5 contributing investment analysts is to buy stock in Cellectis. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 1 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 1 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/3/2021OppenheimerInitiated CoverageBuy$33.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
6/1/2021William BlairReiterated RatingBuyHigh
i
Rating by R. Prasad at William Blair
5/27/2021Robert W. BairdReiterated RatingBuy$39.00High
i
5/4/2021GuggenheimReiterated RatingBuy ➝ NeutralN/A
i
4/29/2021Robert W. BairdReiterated RatingBuy$39.00High
i
4/28/2021GuggenheimDowngradeBuy ➝ NeutralHigh
i
3/16/2021Robert W. BairdUpgradeNeutral ➝ Outperform$23.00 ➝ $39.00High
i
3/8/2021William BlairReiterated RatingOutperformHigh
i
Rating by R. Prasad at William Blair
11/18/2020William BlairReiterated RatingBuyMedium
i
10/15/2020Robert W. BairdDowngradeOutperform ➝ NeutralHigh
i
Rating by Madhu Kumar at Robert W. Baird
8/19/2020CitigroupUpgradeNeutral ➝ Buy$15.00 ➝ $32.00High
i
8/6/2020OppenheimerReiterated RatingBuy$33.00Medium
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/7/2020Robert W. BairdLower Price TargetOutperform$28.00 ➝ $21.00High
i
Rating by Madhu Kumar at Robert W. Baird
5/11/2020Robert W. BairdInitiated CoverageOutperform$20.00Medium
i
5/7/2020OppenheimerReiterated RatingBuy$35.00High
i
3/6/2020CitigroupBoost Price TargetNeutral$14.00 ➝ $16.00Medium
i
3/6/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$15.00 ➝ $11.00High
i
2/19/2020BTIG ResearchBoost Price TargetBuy$37.00 ➝ $39.00High
i
1/13/2020William BlairReiterated RatingBuyHigh
i
12/16/2019Nomura SecuritiesReiterated RatingBuy$73.00Low
i
8/12/2019The Goldman Sachs GroupSet Price TargetHold$20.00High
i
Rating by Salveen Richter at The Goldman Sachs Group, Inc.
8/9/2019BTIG ResearchInitiated CoverageBuy ➝ Buy$37.00High
i
5/24/2019CitigroupReiterated RatingNeutral ➝ Neutral$22.00Medium
i
3/13/2019William BlairInitiated CoverageOutperformMedium
i
Rating by R. Prasad at William Blair
3/13/2019BarclaysReiterated RatingBuy$50.00High
i
3/11/2019CitigroupLower Price TargetNeutral$37.00 ➝ $22.00High
i
12/19/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$25.00High
i
11/25/2018OppenheimerSet Price TargetBuy$44.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
7/16/2018BarclaysInitiated CoverageOverweight$50.00High
i
6/12/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$40.00 ➝ $44.00Low
i
3/16/2018GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
i
3/14/2018Nomura SecuritiesBoost Price TargetBuy$73.00High
i
12/28/2017OppenheimerReiterated RatingOutperform$40.00 ➝ $40.00Low
i
10/29/2017Jefferies Financial GroupReiterated RatingBuy$47.00N/A
i
Rating by Eun Yang at Jefferies Financial Group Inc.
10/6/2017SunTrust BanksReiterated RatingHold$20.00N/A
i
9/26/2017Jefferies Financial GroupReiterated RatingBuy$47.00Low
i
Rating by Eun Yang at Jefferies Financial Group Inc.
9/6/2017Nomura SecuritiesLower Price TargetBuy$49.00 ➝ $43.00Low
i
9/5/2017SunTrust BanksDowngradeBuy ➝ Hold$35.00 ➝ $20.00High
i
9/5/2017Wells Fargo & CompanyReiterated RatingOutperform ➝ Outperform$33.00 ➝ $40.00High
i
8/25/2017Jefferies Financial GroupSet Price TargetBuy$47.00High
i
6/3/2017OppenheimerReiterated RatingBuyLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
5/10/2017OppenheimerSet Price TargetBuy$40.00Low
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
4/26/2017Jefferies Financial GroupReiterated RatingBuy$47.00Low
i
3/21/2017OppenheimerReiterated RatingBuyLow
i
Rating by Hartaj Singh at Oppenheimer Holdings Inc.
3/1/2017Nomura InstinetInitiated CoverageBuy ➝ Buy$49.00N/A
i
3/1/2017Nomura SecuritiesInitiated CoverageBuyN/A
i
2/28/2017Wells Fargo & CompanyInitiated CoverageOutperform ➝ OutperformN/A
i
11/24/2016Piper Jaffray CompaniesSet Price TargetBuy$41.00N/A
i
Rating by Joshua Schimmer at Piper Jaffray Companies
9/14/2016OppenheimerReiterated RatingOutperform$65.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
9/9/2016Jefferies Financial GroupReiterated RatingBuy$47.00N/A
i
Rating by gena wang at Jefferies Financial Group Inc.
8/5/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Gena Wang at Jefferies Financial Group Inc.
7/27/2016OppenheimerReiterated RatingOutperform$65.00N/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
6/20/2016OppenheimerReiterated RatingBuyN/A
i
Rating by Christopher Marai at Oppenheimer Holdings Inc.
(Data available from 6/14/2016 forward)
Cellectis logo
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. The company was founded in 1999 and is headquartered in Paris, France.
Read More

Today's Range

Now: $15.80
$15.48
$16.13

50 Day Range

MA: $17.04
$14.36
$20.24

52 Week Range

Now: $15.80
$14.18
$34.71

Volume

197,891 shs

Average Volume

358,803 shs

Market Capitalization

$718.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Cellectis?

The following equities research analysts have issued reports on Cellectis in the last year: Citigroup Inc., Guggenheim, Oppenheimer Holdings Inc., Robert W. Baird, TheStreet, William Blair, and Zacks Investment Research.
View the latest analyst ratings for CLLS.

What is the current price target for Cellectis?

3 Wall Street analysts have set twelve-month price targets for Cellectis in the last year. Their average twelve-month price target is $34.67, suggesting a possible upside of 119.4%. Robert W. Baird has the highest price target set, predicting CLLS will reach $39.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $32.00 for Cellectis in the next year.
View the latest price targets for CLLS.

What is the current consensus analyst rating for Cellectis?

Cellectis currently has 1 hold rating and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CLLS will outperform the market and that investors should add to their positions of Cellectis.
View the latest ratings for CLLS.

What other companies compete with Cellectis?

How do I contact Cellectis' investor relations team?

Cellectis' physical mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company's listed phone number is 33-1-81-69-16-00 and its investor relations email address is [email protected] The official website for Cellectis is www.cellectis.com.